Texas Children’s Hospital is ranked as one of the nation’s top children’s hospitals by U.S. News & World Report. Our mission is to create a healthier future for children and women throughout our global community by leading in patient care, education and research.
Texas Children’s hospital has hired Dr. Rajalaxmi Natarajan to create new scientific research content for Cain labs and NRI websites. A cell and neurobiologist by training, she will write succinct synopses of ground-breaking epilepsy research conducted at Cain labs and elsewhere in the globe.
Dr. Matthew Weston, postdoctoral fellow at Dr. Swann’s lab received the prestigious NIH Pathway to Independence grant (K99/R00) for his research proposal titled, “Regulation of Synapse and network dynamics by mTOR”. This grant mechanism is designed to facilitate a timely and easier transition from a mentored postdoctoral research position to a stable independent research position.
The Cain Laboratories and Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children’s and Baylor College of Medicine welcome a new faculty member, Dr. Mingshan Xue.
Dr. Swann conducted a workshop entitled, “Understanding Infantile Spasms: a Pathogenic Perspective” at the American Epilepsy Society’s 5th Biennial North American Regional Epilepsy Congress between December 5-9, 2014 at Seattle, Washington.
Loss of 2 genes that repress mechanistic Target of Rapamycin (mTOR), a growth-promoting pathway, causes autism and epilepsy. Excessive excitation of neurons was assumed to be the culprit. However, a study published in the February 2014 issue of The Frontiers in Molecular Neuroscience adds a new twist.
A study by Nakamura et al, published in the September 2013 issue of Neurology explores the association between SCN2A mutations and severe forms of early onset epileptic encephalopathies (EOEE).
A recent study published in the Annals of Neurology by Dr. Lennart Mucke’s team at the Gladstone Institute of Neurological Disease in the University of California at San Francisco demonstrates that genetic ablation of tau in a mouse model of Dravet syndrome reverses most of the symptoms.